Who
Benjamin R. Yerxa
President
Company insider
Files Form 4 as: President, Opus Genetics; Director, Clearside Biomedical; EVP & Chf, Research & Develop, Inspire Pharmaceuticals.
In numbers
- Trades disclosed
- 125
- Buys
- 2
- Sells
- 14
- Bought
- $20K
- Sold
- $276K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 19 Jan 2006
- Last trade
- 23 Jul 2026
- Last filed
- 27 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jul 2026filed 27 Jul 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $22K7,429 at $2.97 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $22K7,429 at $2.97 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $39K7,470 at $5.24 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $39K7,470 at $5.24 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 22 Oct 2025filed 24 Oct 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $46K23,795 at $1.95 | filing |
| 21 Nov 2024filed 25 Nov 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Bought | $9,80010,000 at $0.98 | filing |
| 7 Nov 2024filed 12 Nov 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —332,800 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | Clearside Biomedicaloption or derivative | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 15 May 2024filed 15 May 2024 | Clearside Biomedical | SEC FORM 4 Bought | $10K7,813 at $1.31 | filing |
| 22 Jun 2023filed 23 Jun 2023 | Clearside Biomedicaloption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | Clearside Biomedicaloption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 2 Mar 2022filed 4 Mar 2022 | Clearside Biomedicaloption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 May 2010filed 13 May 2010 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 12 May 2010filed 13 May 2010 | Inspire Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —1,750 at $0.00 | filing |
| 3 May 2010filed 5 May 2010 | Inspire Pharmaceuticals | SEC FORM 4 Sold | $682100 at $6.82 | filing |
| 3 May 2010filed 5 May 2010 | Inspire Pharmaceuticals | SEC FORM 4 Sold | $680100 at $6.80 | filing |
| 3 May 2010filed 5 May 2010 | Inspire Pharmaceuticals | SEC FORM 4 Sold | $26539 at $6.79 | filing |
| 3 May 2010filed 5 May 2010 | Inspire Pharmaceuticals | SEC FORM 4 Sold | $1,092161 at $6.78 | filing |
News
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026Opus Genetics to Present at the Chardan Annual Healthcare ConferenceIRD · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Benjamin R. Yerxa; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.